Maria Rangel to Risk Factors
This is a "connection" page, showing publications Maria Rangel has written about Risk Factors.
Connection Strength
0.227
-
Rangel MO, Kaplan R, Daviglus M, Schneiderman N, Hurwitz BE, Cai J, Gonzalez F, Kitzman D, Kansal M, Rodriguez CJ. Estimation of Incident Heart Failure Risk among US Hispanics/Latinos Using a Validated Echocardiographic Risk-Stratification Index: the Echocardiographic Study of Latinos. J Card Fail. 2018 09; 24(9):622-624.
Score: 0.083
-
Rangel MO, O'Neal WT, Soliman EZ. Usefulness of the Electrocardiographic P-Wave Axis as a Predictor of Atrial Fibrillation. Am J Cardiol. 2016 Jan 01; 117(1):100-4.
Score: 0.067
-
Kotini-Shah P, Duran-Luciano P, Kansal M, Nasrollahi F, Lee UJ, Yuan Y, Rangel MO, Kaplan R, Ponce SG, Shah SJ, Cai J, Bilsker MS, Pu M, Hurwitz BE, Rodriguez CJ. Global Longitudinal Strain Reference Values in the Hispanic/Latino Population: Echocardiographic Study of Latinos (ECHO-SOL). Am J Cardiol. 2026 Feb 15; 261:41-49.
Score: 0.034
-
Doukky R, Hayes K, Frogge N, Balakrishnan G, Dontaraju VS, Rangel MO, Golzar Y, Garcia-Sayan E, Hendel RC. Impact of appropriate use on the prognostic value of single-photon emission computed tomography myocardial perfusion imaging. Circulation. 2013 Oct 08; 128(15):1634-43.
Score: 0.015
-
Doukky R, Rangel MO, Wassouf M, Dick R, Alqaid A, Morales Demori R. The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation. J Nucl Cardiol. 2013 Apr; 20(2):205-13.
Score: 0.014
-
Doukky R, Rangel MO, Dick R, Wassouf M, Alqaid A, Margeta B. Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial. Int J Cardiovasc Imaging. 2013 Jun; 29(5):1029-37.
Score: 0.014